Anti-Suicide Market To Worth Over US$ 5.5 Billion with 4.1% CAGR up to 2027 – Technology Snapshot with Solution to Drive Market Growth Vigorously by CMI

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

The Global Anti-Suicide Drugs Market, by Drug Class (Anti-Depressant and Anti-Anxiety Drugs, Anti-Psychotic Drugs, NMDA Antagonist, and Antibiotic Analog) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$ 3,818.1 million in 2018 and is projected to expand at a CAGR of 4.1% during the forecast period (2019–2027). 

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/10

Novel approved drugs, which are expected to be commercialized post-2020, introduced for the treatment of suicidal ideation are expected to drive the global anti-suicide drugs market growth. Until recently, suicidal ideation has been treated with anti-depressants, anti-anxiety, and anti-psychotic drugs. The trend is expected to continue till the expected launch of Cyclurad by NeruoRx Pharma during the latter half of the forecast period (2019–2027).

Cyclurad is a combination of D-cycloserine and Lurasidone indicated for acute suicidal ideation/behavior (ASIB) in bipolar depression. Various other drug candidates are in the pipeline, which are intended for treatment of suicidal ideation in major depressive disorder (MDD).

Suicide is one of the major economic burdens to the global economy. According to the World Health Organization (WHO), each year, over 800,000 people commit suicide. Most of the suicidal deaths occur in Asia, Africa, and Eastern Europe. Moreover, many suicidal attempts go unnoticed and are rarely reported to suicidal prevention organizations. Some of the leading suicide prevention organizations include Stop Suicide, Yellow Ribbon Suicide Prevention Program, and American Foundation for Suicide Prevention. In India, Sneha India Foundation is among the major organizations who provide 24X7 helpline and focuses on offering unconditional emotional support to desperate, depressed, and suicidal people.

Quick Buy – Anti-Suicide Drugs Market Research Report: https://www.coherentmarketinsights.com/insight/buy-now/10

High prevalence of depression that leads to suicidal attempts and deaths along with the introduction of novel drugs are major factors driving growth of the anti-suicide drugs market. According to the FDA, depression acts as a disabling and stigmatizing illness, which is expected to lead to suicide among young people and adolescents. Therefore, pharmaceutical companies are launching specific drugs for suicidal impulses, which is expected to drive growth of the market over the forecast period. N-Methyl-D-aspartate receptor (NMDAR) agonists and antagonist are considered as the prospective candidates for the treatment of suicidal ideation. The companies that bank on anti-depressants and anti-psychotic drugs for treatment of patients who are at risk of suicide should reconsider their strategy, as these are found to be ineffective at solving this issue. The major factor driving growth of the global anti-suicide drugs market is the off-label recommendations and prescriptions of anti-depressants, anti-anxiety, and anti-psychotic drugs. However, inadequate reach of healthcare facilities and affordable medications is a major factor restraining growth of the overall healthcare market in emerging economies such as India, China, Brazil, and Indonesia. Therefore, companies that are introducing novel anti-suicidal drugs are expected to find difficulty in market penetration in these nations and would be able to capture only a part of these markets to capitalize on the lucrative growth opportunities in these regions. North America and Europe remain potential markets at initial stages for the anti-suicidal drugs. High suicidal rates and accessibility to better medical therapies would be major factors contributing to growth of the anti-suicide drugs market in these regions.

Browse 48 Market Data Tables and 44 Figures spread through 150 Pages and in-depth TOC on “ Anti-Suicide Drugs Market, by Drug Class (Anti-Depressant and Anti-Anxiety Drugs, Anti-Psychotic Drugs, NMDA Antagonist, Antibiotic Analog), by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Global Forecast to 2027″

To know the latest trends and insights prevalent in the anti-suicide drugs market press release, click the link below: https://www.coherentmarketinsights.com/press-release/anti-suicide-drugs-market-to-surpass-us-48-billion-by-2024-52

Key takeaways of the market:

• The global anti-suicide drugs market is majorly characterized by the use of anti-depressants, anti-anxiety, and anti-psychotic drugs
• The global anti-suicide drugs market is expected to expand at a CAGR of 4.1% during the forecast period (2019–2027), owing to rising incidence of suicides across the globe
• Suicidal rates are higher in Asia, Eastern Europe, and Africa regions
• The antibiotic analog (NMDA agonist) segment in the global anti-suicide drugs market is estimated to be growing faster post its FDA approval and commercialization
• Market growth of anti-depressants and anti-anxiety drugs are projected to be impacted negatively by the launch of FDA approved anti-suicidal drugs towards the latter-half of the forecast period
• Some of the major players operating in the global anti-suicide drugs market include Pfizer, Inc., AstraZeneca plc, Eli Lilly and Company, Allergan plc, GlaxoSmithKline plc, Merck & Co., Inc., H. Lundbeck A/S, NeuroRx, Inc., and Johnson & Johnson

Table of Contents

1. Research Objective and assumption
   • Research Objectives
   • Assumptions
   • Abbreviations
2. Market Purview
   • Report Description
     • Market Definition and Scope
   • Executive Summary
     • Market Snippet By Drug Class
     • Market Snippet By Geography
   • Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restraints
     • Market Opportunities
   • Epidemiology
   • Healthcare Spending
   • PEST Analysis
   • Pipeline Analysis
   • Anti-Suicide Prevention Campaigns and Programs
4. Global Anti-Suicide Drugs Market, By Drug Class, 2016 – 2027 (US$ Million)
   • Introduction
     • Market Share Analysis, 2019 and 2027 (%)
     • Y-O-Y Growth Analysis, 2016 – 2027
     • Segment Trends
   • Anti-Depressant and Anti-Anxiety Drugs
   • Anti-Psychotic Drugs
   • NMDA Antagonist
   • Antibiotic Analog
5. Global Anti-Suicide Drugs Market, By Geography, 2016 – 2027 (US$ Million)
   • Introduction
     • Market Share Analysis, By Region, 2019 and 2027 (%)
     • Y-O-Y Growth Analysis, For Regions, 2016 – 2027
   • North America
     • Market Share Analysis, By Country, 2019 and 2027 (%)
     • Y-O-Y Growth Analysis, By Country, 2016 – 2027
       • U.S.
         • Country Trends
         • Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
       • Canada
         • Country Trends
         • Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
   • Europe
     • Market Share Analysis, By Country, 2019 and 2027 (%)
     • Y-O-Y Growth Analysis, By Country, 2016 – 2027
       • U.K.
         • Country Trends
         • Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
       • Germany
         • Country Trends
         • Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
       • Italy
         • Country Trends
         • Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
       • France
         • Country Trends
         • Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
       • Spain
         • Country Trends
         • Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
       • Russia
         • Country Trends
         • Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
       • Rest of Europe
         • Country Trends
         • Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
   • Asia Pacific
     • Market Share Analysis, By Country, 2019 and 2027 (%)
     • Y-O-Y Growth Analysis, By Country, 2016 – 2027
       • China
         • Country Trends
         • Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
       • India
         • Country Trends
         • Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
       • Japan
         • Country Trends
         • Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
       • ASEAN
         • Country Trends
         • Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
       • Australia
         • Country Trends
         • Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
       • South Korea
         • Country Trends
         • Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
       • Rest of Asia Pacific
         • Country Trends
         • Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
   • Latin America
     • Market Share Analysis, By Country, 2019 and 2027 (%)
     • Y-O-Y Growth Analysis, By Country, 2016 – 2027
       • Brazil
         • Country Trends
         • Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
       • Mexico
         • Country Trends
         • Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
       • Argentina
         • Country Trends
         • Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
       • Rest of Latin America
         • Country Trends
         • Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
   • Middle East
     • Market Share Analysis, By Country, 2019 and 2027 (%)
     • Y-O-Y Growth Analysis, By Country, 2016 – 2027
       • GCC Countries
         • Country Trends
         • Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
       • Israel
         • Country Trends
         • Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
       • Rest of Middle East
         • Country Trends
         • Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
   • Africa
     • Market Share Analysis, By Country, 2019 and 2027 (%)
     • Y-O-Y Growth Analysis, By Country, 2016 – 2027
       • Northern Africa
         • Country Trends
         • Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
       • Central Africa
         • Country Trends
         • Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
       • South Africa
         • Country Trends
         • Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
6. Competitive Landscape
   • Heat Map Analysis
   • Company Profiles
     • Pfizer, Inc.
       • Company Overview
       • Product Portfolio
       • Financial Performance
       • Key Developments
       • Market Presence
     • AstraZeneca plc
     • Eli Lilly and Company
     • Allergan plc
     • GlaxoSmithkline plc
     • Merck & Co., Inc.
     • H. Lundbeck A/S
     • NeuroRx, Inc.
     • Johnson & Johnson
7. Section
   • References
   • Research Methodology
   • About us and Sales Contact

Special Requirements?
We value your investment and offer customization as per your requirements.

Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/10

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837